
For six years, former Novo Nordisk researcher Dorte X. Gram has been developing the diabetes tablet XEN-D0501 in the Swedish startup Pila Pharma – with the help of her son, investors, consultants and a handful of coworkers.
Initially, the plan was to track down a collaborate partner, who could take the drug further. But now that the phase IIa study showed promising results, she has decided to raise the ambitions of the company instead.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app